Evidence map›Paper›PMID 39102878›Full record

ArticleJournal of the National Cancer Institute. Monographs2024

NCI SEER-Linked Virtual Tissue Repository Pilot.

Pamela Sanchez, Alison L Van Dyke, Valentina I Petkov, Yao Yuan, Sarah Bonds, Connor Valenzuela, Alyssa W Tuan, Radim Moravec, Sean F Altekruse, Aatur D Singhi and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute. Monographs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Pamela SanchezSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Alison L Van DykeSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.ORCID 0000-0002-8591-9467
Valentina I PetkovSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Yao YuanSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Sarah BondsSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Connor ValenzuelaSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Alyssa W TuanSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Radim MoravecSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Sean F AltekruseSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Aatur D SinghiDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Kate M SerdyDepartment of Pathology, Allegheny Health Network, Pittsburgh, PA, USA.
Yun WuDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rosemary D CressPublic Health Institute, Cancer Registry of Greater California, Sacramento, CA, USA.
Jennifer A DohertyThe Utah Cancer Registry, Salt Lake City, UT, USA.
Lloyd MuellerConnecticut Tumor Registry, Connecticut State Department of Public Health, Hartford, CT, USA.
Brenda Y HernandezThe Hawaii Tumor Registry, University of Hawaii Cancer Center, Honolulu, HI, USA.
Charles F LynchThe Iowa Cancer Registry, The University of Iowa, Iowa City, IA, USA.
Thomas C TuckerKentucky Cancer Registry, Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
Xiao-Cheng WuThe Louisiana Tumor Registry, Louisiana State University School of Public Health, New Orleans, LA, USA.ORCID 0000-0003-3663-5027
Lynn MatrisianScientific and Medical Affairs, Pancreatic Cancer Action Network (PanCAN), Manhattan Beach, CA, USA.ORCID 0000-0002-5631-2826
Lynne PenberthySurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
HHS HHSN261201800002INational Institutes of HealtNCI NIH HHS HHSN261201300009CNCI NIH HHS HHSN261201300009INCI NIH HHS HHSN261201800002BNCI NIH HHS HHSN261201800002CNCI NIH HHS HHSN261201800007CNCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800012CNCI NIH HHS HHSN261201800012INCI NIH HHS HHSN261201800013CNCI NIH HHS HHSN261201800013INCI NIH HHS HHSN261201800016CNCI NIH HHS HHSN261201800016INCI NIH HHS P30 CA177558NIH HHSPancreatic Cancer Action NetworkPublic Health Institute, Cancer Registry of Greater CaliforniaSchool of Public Health Louisiana State University Health New Orleans HHSN261201800007ISurveillance Research Program, Division of Cancer Control and Population SciencesUniversity of Hawaii Cancer Center
6 · The paper itself

Abstract

backgroundThe Surveillance, Epidemiology, and End Results (SEER) Program with the National Cancer Institute tested whether population-based cancer registries can serve as honest brokers to acquire tissue and data in the SEER-Linked Virtual Tissue Repository (VTR) Pilot.

methodsWe collected formalin-fixed, paraffin-embedded tissue and clinical data from patients with pancreatic ductal adenocarcinoma (PDAC) and breast cancer (BC) for two studies comparing cancer cases with highly unusual survival (≥5 years for PDAC and ≤30 months for BC) to pair-matched controls with usual survival (≤2 years for PDAC and ≥5 years for BC). Success was defined as the ability for registries to acquire tissue and data on cancer cases with highly unusual outcomes.

resultsOf 98 PDAC and 103 BC matched cases eligible for tissue collection, sources of attrition for tissue collection were tissue being unavailable, control paired with failed case, second control that was not requested, tumor necrosis ≥20%, and low tumor cellularity. In total, tissue meeting the study criteria was obtained for 70 (71%) PDAC and 74 (72%) BC matched cases. For patients with tissue received, clinical data completeness ranged from 59% for CA-19-9 after treatment to >95% for margin status, whether radiation therapy and chemotherapy were administered, and comorbidities.

conclusionsThe VTR Pilot demonstrated the feasibility of using SEER cancer registries as honest brokers to provide tissue and clinical data for secondary use in research. Studies using this program should oversample by 45% to 50% to obtain sufficient sample size and targeted population representation and involve subspecialty matter expert pathologists for tissue selection.

Indexed as

Breast NeoplasmsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsSEER ProgramAdultAgedCase-Control StudiesFemaleHumansMaleMiddle AgedNational Cancer Institute (U.S.)Pilot ProjectsRegistriesTissue BanksUnited States

Identifiers

PMID39102878
PMCPMC11300006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.